Get the Stockscreener App
0.1667
1.30%
-0.0022
Viracta Therapeutics Inc stock is traded at $0.1667, with a volume of 495.41K.
It is down -1.30% in the last 24 hours and down -20.62% over the past month.
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
See More
Previous Close:
$0.1689
Open:
$0.1772
24h Volume:
495.41K
Relative Volume:
0.19
Market Cap:
$6.63M
Revenue:
-
Net Income/Loss:
$-43.29M
P/E Ratio:
-0.1515
EPS:
-1.1
Net Cash Flow:
$-34.80M
1W Performance:
-1.88%
1M Performance:
-20.62%
6M Performance:
-69.55%
1Y Performance:
-67.38%
1-Day Range:
$0.1579
$0.1772
1-Week Range:
$0.152
$0.188
52-Week Range:
$0.1315
$1.31
Viracta Therapeutics Inc Stock (VIRX) Company Profile
Name
Viracta Therapeutics Inc
Sector
Industry
Phone
858-400-8470
Address
2533 S COAST HWY 101, CARDIFF
Compare VIRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIRX
Viracta Therapeutics Inc
|
0.1667 | 6.63M | 0 | -43.29M | -34.80M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Viracta Therapeutics Inc Stock (VIRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-16-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-01-22 | Initiated | RBC Capital Mkts | Outperform |
| May-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-26-21 | Initiated | SVB Leerink | Outperform |
| Mar-25-21 | Initiated | Evercore ISI | Outperform |
Viracta Therapeutics Inc Stock (VIRX) Latest News
Viracta Therapeutics faces Nasdaq delisting over audit issue By Investing.com - Investing.com Canada
Viracta Therapeutics faces Nasdaq delisting over audit issue - MSN
Finance Watch: As Cash Dwindles, Biotechs Cut Costs, Sell Assets, Merge, Assess Options - News & Insights
North American Morning Briefing : Boeing Stock -2- - Marketscreener.com
Viracta Therapeutics (NASDAQ:VIRX) Given “Neutral” Rating at Rodman & Renshaw - Defense World
Rodman & Renshaw Downgrades Viracta Therapeutics (VIRX) - MSN
Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure - Yahoo Finance
Deal Dispatch: Party City Wraps Up, Big Lots Goes Bust, The Container Store Continues - Benzinga
Castellum, Viracta Therapeutics And 3 Stocks To Watch Heading Into Friday (CORRECTED) - Benzinga
ServiceTitan initiated, Viracta downgraded: Wall Street's top analyst calls - Yahoo Finance
Viracta stock falls on strategic review (VIRX:NASDAQ) - Seeking Alpha
Masimo To Rally More Than 13%? Here Are 5 Top Analyst Forecasts For Friday - Benzinga
Constellium, Viracta Therapeutics And 3 Stocks To Watch Heading Into Friday - Benzinga
Viracta Therapeutics, Inc. Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives - Marketscreener.com
Viracta Therapeutics Ends Naval-1 Clinical Trial and Is Exploring Strategic Alternatives - MarketWatch
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives - GlobeNewswire
Viracta Therapeutics (VIRX) Halts Phase 2 NAVAL-1 Trial, Explores Strategic Alternatives Amid Resource Conservation - StockTitan
Viracta Therapeutics' SWOT analysis: stock focus narrows amid pipeline shift - Investing.com
Viracta Therapeutics, Inc. (NASDAQ:VIRX) Short Interest Update - Defense World
Viracta Therapeutics Inc (NASDAQ: VIRX) Has Great Upside Potential - Stocks Register
Viracta Therapeutics' SWOT analysis: focused strategy reshapes stock outlook By Investing.com - Investing.com Australia
Epstein-Barr Virus (EBV) Market A Deep Dive into Current - openPR
Viracta Therapeutics' SWOT analysis: focused strategy reshapes stock outlook - Investing.com
Viracta Therapeutics faces Nasdaq delisting over non-compliance By Investing.com - Investing.com Australia
Viracta Therapeutics faces Nasdaq delisting over non-compliance - Investing.com
Viracta Therapeutics faces Nasdaq delisting risk - Investing.com India
Viracta Therapeutics faces Nasdaq delisting risk By Investing.com - Investing.com Canada
Volkswagen Ag ADR (VWAGY) QuotePress Release - The Globe and Mail
Contrasting ALX Oncology (NASDAQ:ALXO) & Viracta Therapeutics (NASDAQ:VIRX) - Defense World
Royal Bank of Canada Cuts Viracta Therapeutics (NASDAQ:VIRX) Price Target to $2.00 - Defense World
VIRX stock touches 52-week low at $0.15 amid market challenges - Investing.com UK
Viracta Therapeutics Highlights Strategic Focus and Financials - TipRanks
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
Sunesis: Q3 Earnings Snapshot - mySA
Viracta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Head and Neck Cancer Market Expected to Reach $9.07 Billion by 2030, Growing at 16.2% CAGR As Revealed In N... - WhaTech
Natural Killer T-Cell Lymphoma Market 2024 Projections, - openPR
Viracta Thera pins hopes on lead lymphoma program - The Pharma Letter
VIRX stock touches 52-week low at $0.18 amid market challenges - Investing.com UK
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma - The Manila Times
Viracta Therapeutics cuts workforce to focus on cancer program - Investing.com
Viracta Therapeutics Inc Stock (VIRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):